Bio-rad Laboratories, Inc. Earnings

Bio-rad Laboratories, Inc.’s revenue fell -4.16% since last year same period to $585.4Mn in the Q1 2025. On a quarterly growth basis, Bio-rad Laboratories, Inc. has generated -12.3% fall in its revenue since last 3-months.

Bio-rad Laboratories, Inc.’s net profit fell -99.98% since last year same period to $0.06Mn in the Q1 2025. On a quarterly growth basis, Bio-rad Laboratories, Inc. has generated 100.01% jump in its net profits since last 3-months.

Bio-rad Laboratories, Inc.’s net profit margin fell -99.98% since last year same period to 0.01% in the Q1 2025. On a quarterly growth basis, Bio-rad Laboratories, Inc. has generated 100.01% jump in its net profit margins since last 3-months.

Bio-rad Laboratories, Inc.’s earning per share (EPS) estimates for the current quarter stand at 1.78 - a -38.2% fall from last quarter’s estimates.

Bio-rad Laboratories, Inc.’s earning per share (EPS) estimates for the current year stand at 1.78.

Bio-rad Laboratories, Inc.’s earning per share (EPS) jumped 10.92% since last year same period to 2.54 in the Q1 2025. This indicates that the Bio-rad Laboratories, Inc. has generated 10.92% annual rate of jump in its earning per share (EPS) in the last 4 quarters.

Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. Bio-rad Laboratories, Inc.’s return on assets (ROA) stands at 0.02.

The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. Bio-rad Laboratories, Inc.’s return on equity (ROE) stands at -0.28.